Michael Rosen, M.D

Michael Rosen, M.D., is a professor of Pharmacology and Pediatrics at Columbia University College of Physicians and Surgeons in New York, and a full-time cardiovascular researcher. He serves as associate director of the recently established Partnership for Women's Health at Columbia, a research initiative focusing solely on gender-specific medicine: the science of how human biology differs between women and men. Dr. Rosen is also principal investigator on a Program Project Grant funded by the National Heart, Lung and Blood Institute.

Dr. Rosen left the clinical arena in 1975 to devote his efforts full time to basic cardiovascular research. He and his associates have made many contributions in the initiation of cardiac arrhythmias and determining the mechanism of action of a number of antiarrhythmic drugs.

Dr. Rosen has authored more than 250 papers, books and chapters in medical literature. In addition to serving on the editorial board of numerous journals, he is currently editor-in-chief of the Journal of Cardiovascular Pharmacology, and was formerly associate editor of Circulation Research, and field editor for the Journal of Pharmacology and Experimental Therapeutics.

Since 1978, he has been active on the Board of Regents of the American College of Clinical Pharmacology, where he was appointed Honorary Regent for Life. Dr. Rosen served on the board of directors of both the national American Heart Association (AHA) and is currently on the board of its New York City affiliate. He was chair of the AHA Scientific Program Committee from 1988-91, chair of the Task Force on Strategies to Increase Federal Funding of Research in 1990, and is immediate past chair of the Basic Science Council. In addition, in 1992, he received the AHA Award of Merit.

Dr. Rosen is also active internationally in a variety of ways. He is currently professor of basic medicine at Moscow State University in Russia, as well as a member of the scientific advisory committee of the Rappaport Institute in Haifa, Israel, and for the Ad Hoc Group for Medical Research Funding.